Piperacillin–tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae-Reference-Cited by-同舟云学术

Piperacillin–tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae

Published:2012-05 Issue:5 Volume:64 Page:533-534
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Kang Cheol-In,Park So Yeon,Chung Doo Ryeon,Peck Kyong Ran,Song Jae-Hoon

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference8 articles.

1. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria;Chen;J Infect,2011

2. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin–tazobactam against extended-spectrum-beta-lactamase-producing E. coli and Klebsiella species;Gavin;Antimicrob Agents Chemother,2006

3. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin–tazobactam;Peterson;Clin Microbiol Infect,2008

4. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing E. coli: a post hoc analysis of prospective cohorts;Rodriguez-Bano;Clin Infect Dis,2012

5. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases;Paterson;Clin Infect Dis,2004

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysis;Journal of Global Antimicrobial Resistance;2024-12

2. No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study;Microbiology Spectrum;2024-07-02

3. Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use;World Journal of Emergency Surgery;2024-06-08

4. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP;Antibiotics;2024-03-25

5. WITHDRAWN: Antibiotic Bacteria Interaction: Dataset and Benchmarking;2024-02-24